GlassScriptPhysician profile
Luann Deafenbaugh
NPI 1003058454
$4,041.79
in general payments reported to CMS, 2019-2025
37 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $604 · 2022: $438 · 2023: $975 · 2024: $778 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.88 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $569.63 | 2021-2025 | |
| Janssen Biotech, INC. | $407.26 | 2021-2025 | Tecvayli, Darzalex, Rybrevant |
| Merck Sharp & Dohme LLC | $340.52 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Incyte Corporation | $272.33 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $203.97 | 2021 | |
| Eisai INC. | $165.49 | 2023-2025 | |
| Seagen INC. | $152.25 | 2021-2023 | Adcetris |
| Amgen INC. | $145.05 | 2021-2023 | Kyprolis, Lumakras, Blincyto |
| Regeneron Healthcare Solutions, INC. | $144.32 | 2021-2025 | Libtayo |
| Abbvie INC. | $136.68 | 2023-2025 | |
| Celgene Corporation | $131.50 | 2022-2023 | Pomalyst, Opdualag, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $123.81 | 2025 | Enhertu, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $119.19 | 2024-2025 | Opdivo |
| Pfizer INC. | $111.45 | 2022-2024 | |
| Adaptive Biotechnologies Corporation | $108.00 | 2024-2025 | Clonoseq |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luann Deafenbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.